MBX Biosciences, Inc. (MBX)

MBX Biosciences Statistics

Total Valuation

MBX Biosciences has a market cap or net worth of $1.44 billion. The enterprise value is $1.00 billion.

Market Cap	1.44B
Enterprise Value	1.00B

Important Dates

The last earnings date was Thursday, May 7, 2026, before market open.

Earnings Date	May 7, 2026
Ex-Dividend Date	n/a

Share Statistics

MBX Biosciences has 47.60 million shares outstanding. The number of shares has increased by 112.87% in one year.

Current Share Class	47.60M
Shares Outstanding	47.60M
Shares Change (YoY)	+112.87%
Shares Change (QoQ)	+3.81%
Owned by Insiders (%)	2.92%
Owned by Institutions (%)	75.65%
Float	29.55M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	3.29
P/TBV Ratio	3.29
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 30.79, with a Debt / Equity ratio of 0.00.

Current Ratio	30.79
Quick Ratio	30.42
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -25.73% and return on invested capital (ROIC) is -18.33%.

Return on Equity (ROE)	-25.73%
Return on Assets (ROA)	-17.68%
Return on Invested Capital (ROIC)	-18.33%
Return on Capital Employed (ROCE)	-22.55%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	n/a
Profits Per Employee	-$1.37M
Employee Count	63
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +122.08% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+122.08%
50-Day Moving Average	32.05
200-Day Moving Average	27.59
Relative Strength Index (RSI)	43.10
Average Volume (20 Days)	740,949

Short Selling Information

The latest short interest is 4.28 million, so 9.00% of the outstanding shares have been sold short.

Short Interest	4.28M
Short Previous Month	4.03M
Short % of Shares Out	9.00%
Short % of Float	14.50%
Short Ratio (days to cover)	6.76

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-98.79M
Pretax Income	-86.61M
Net Income	-86.61M
EBITDA	-98.56M
EBIT	-98.79M
Earnings Per Share (EPS)	-$2.18

Balance Sheet

The company has $439.98 million in cash and $555,000 in debt, with a net cash position of $439.42 million or $9.23 per share.

Cash & Cash Equivalents	439.98M
Total Debt	555,000
Net Cash	439.42M
Net Cash Per Share	$9.23
Equity (Book Value)	437.76M
Book Value Per Share	9.20
Working Capital	433.97M

Cash Flow

In the last 12 months, operating cash flow was -$77.48 million and capital expenditures -$2.34 million, giving a free cash flow of -$79.82 million.

Operating Cash Flow	-77.48M
Capital Expenditures	-2.34M
Depreciation & Amortization	235,000
Net Borrowing	n/a
Free Cash Flow	-79.82M
FCF Per Share	-$1.68

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

MBX Biosciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-112.87%
Shareholder Yield	-112.87%
Earnings Yield	-6.01%
FCF Yield	-5.54%

Analyst Forecast

The average price target for MBX Biosciences is $69.09, which is 128.17% higher than the current price. The consensus rating is "Buy".

Price Target	$69.09
Price Target Difference	128.17%
Analyst Consensus	Buy
Analyst Count	12
Revenue Growth Forecast (3Y)	n/a
EPS Growth Forecast (3Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2